Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes

<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...

Full description

Bibliographic Details
Main Authors:	Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ
Format:	Journal article
Published:	American Medical Association 2018

Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes by Lotta, L, Stewart, I, Sharp, S, Day, F, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, L, Kerrison, N, Khaw, K, McCarthy, M, O'Rahilly, S, Scott, R, Savage, D, Perry, J, Langenberg, C, Wareham, N

Published 2018

Journal article

Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes

Similar Items